Beam Therapeutics Inc. (BEAM) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Beam Therapeutics Inc. (BEAM) Earnings Overview
As of June 22, 2026, Beam Therapeutics Inc. (BEAM) reported trailing twelve-month net income of -$65M, reflecting +82.3% year-over-year growth. The company earned $-0.63 per diluted share over the past four quarters, with a net profit margin of -57.2%.
Looking at the long-term picture, BEAM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2017.
Beam Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$109M net income, -395.0% margin), CRSP (-$569M net income, -16569.8% margin), NTLA (-$395M net income, -609.9% margin), BEAM has outperformed on profitability metrics. Compare BEAM vs EDIT →
BEAM Earnings vs Peers
Earnings metrics vs comparable public companies
BEAM Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$80M | +78.8% | -$384M | $-0.81 | -57.2% | -274.6% |
| 2024 | -$377M | -184.3% | -$416M | $-4.58 | -593.1% | -654.3% |
| 2023 | -$133M | +54.2% | -$176M | $-1.72 | -35.1% | -46.7% |
| 2022 | -$289M | +22.0% | -$338M | $-4.13 | -474.5% | -555.6% |
| 2021 | -$371M | -90.5% | -$392M | $-5.77 | -714.9% | -757.0% |
| 2020 | -$195M | -148.4% | -$133M | $-5.49 | -810800.0% | -553166.7% |
| 2019 | -$78M | +32.0% | -$75M | $-1.53 | -435144.4% | -417522.2% |
| 2018 | -$115M | -1220.3% | -$46M | $-3.28 | - | - |
| 2017 | -$9M | - | -$9M | $-0.62 | - | - |
Download Data
Export BEAM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BEAM — Frequently Asked Questions
Quick answers to the most common questions about buying BEAM stock.
What is BEAM earnings per share (EPS)?
BEAM trailing twelve-month (TTM) diluted EPS is $-0.63, reflecting +82.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Beam Therapeutics Inc.'s net income?
Beam Therapeutics Inc. (BEAM) trailing twelve-month net income is $-65M as of 2025. Earnings grew +82.3% year-over-year.
Is BEAM profitable?
BEAM is not currently profitable on a TTM basis, reporting a net loss of $-65M. Net margin is -57.2%. Investors should monitor for a return to profitability.
What is BEAM's earnings growth rate?
BEAM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are BEAM's profit margins?
Beam Therapeutics Inc. net profit margin is -57.2%, operating margin is -274.6%, and gross margin is +84.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -8.1%.
Is BEAM growing earnings?
Yes, BEAM earnings are accelerating — EPS growth of +82.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-65M. Earnings momentum is strengthening.
What was BEAM's best earnings year?
Beam Therapeutics Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were BEAM's earnings last quarter?
BEAM's most recent reported quarter was Q1 2026. Net income was $-94M with diluted EPS of $-0.91. For a full breakdown of all quarters, see the quarterly earnings table on this page.